Grifols is anticipating a period of strong growth on the back of its recently FDA-approved intravenous immunoglobulin product Yimmugo ... has dropped the list of the next 15 drugs to be negotiated ...
The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback